Option chain shows key data for Avatar Ventures's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Avatar Ventures.

Avatar Ventures (OTC:ATAR) Stock, Option Chain

Avatar Ventures Corp intends to be a developer of aftermarket electronic accessories for consumer motor vehicles.

AVATAR VENTURES CORP by Avatar Ventures Corp.

Avatar Ventures Corp

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

Atari SA

Atari Token

UBS analyst Jay Sole upgrades Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) from Neutral to Buy and raises the price target from $173 to $220.

News

Upgrades

Price Target

Analyst Ratings

UBS Upgrades Abercrombie & Fitch to Buy, Raises Price Target to $220

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) from Buy to Buy.

Reiteration

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeuticsto Buy

Piper Sandler analyst Adam Maeder initiates coverage on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral rating and announces Price Target of $252.

Initiation

Piper Sandler Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $252

TECH

Bio-techne Expands R&D Systems AI-engineered Designer Protein Portfolio To Advance Cell Therapy And Regenerative Medicine

IVVD

Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC, Says Data Submitted To FDA, With Timely Update To PEMGARDA Fact Sheet For Healthcare Providers Anticipated

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Buy to Buy.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokineticsto Buy

YMAB

Y-mAbs Internally Realigns Operations With Establishment Of Two Business Units: Radiopharmaceuticals And DANYELZA; Plans Reduction In Its Current Workforce Of Up To 13%

Piper Sandler analyst Anna Andreeva upgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Neutral to Overweight and raises the price target from $72 to $90.

Piper Sandler Upgrades Nike to Overweight, Raises Price Target to $90

<ul>
<li>Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points&nbsp;(p&lt;0.0001, n=10) and 100% of patients in remission at Day 8</li>
<li>Primary endpoint met in phase 2a POC trial in bipolar II disorder with a current major depressive episode with a MADRS reduction from baseline of –16.8 points&nbsp;(p=0.0099, n=6) and 33% of patients in remission at Day 8</li>
<li>In both trials, GH001 was well tolerated and no treatment-related serious adverse events were reported</li>
<li>Inhalation toxicology study in a non-rodent species was completed with no histology findings in the respiratory tract of any dogs in the study at any dose level</li>
<li>Additional inhalation toxicology study in rats was completed supporting our position that respiratory tract histology findings are rat specific</li>
<li>Our response to FDA's request for additional device design verification information is being prepared</li>
<li>Full response to the IND hold planned to be submitted in mid-2025</li>
<li>Top-line data from our randomized, double-blind, placebo-controlled Phase 2b trial in TRD on track to be announced in Q1 2025</li>
</ul>

Biotech

Health Care

General

GHRS

GH Research Said It Met Primary Endpoint In Phase 2a Proof-Of-Concept Trial In Postpartum Depression And Phase 2a Proof-Of-Concept Trial In Bipolar II Disorder With Current Major Depressive Episode

UBS analyst Jay Sole upgrades Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) from Neutral to Buy and raises the price target from $50 to $60.

UBS Upgrades Gildan Activewear to Buy, Raises Price Target to $60

MATW

Matthews International Announced That It Has Filed Definitive Proxy Materials With The Securities And Exchange Commission In Connection With Its Upcoming Annual Meeting Of Shareholders Scheduled To Be Held On February 20

Asset Sales

NovaBay Pharmaceuticals Sells Wound Care Trademarks NeutroPhase, PhaseOne, And OmniPhase To Phase One Health For $500K

"We are pleased to announce that we reached our target enrollment for our 396-patient Phase 2b trial of rezpegaldesleukin," said Howard W. Robin, President and CEO of Nektar Therapeutics.&nbsp;
"We look forward to announcing the topline data from the 16-week induction treatment period in this study in the second quarter of 2025."
&nbsp;

NKTR

Nektar Therapeutics Completes Target Enrollment In REZOLVE-AD Phase 2B Study Of Rezpegaldesleukin In Patients With Atopic Dermatitis

<ul>
<li>Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA</li>
<li>Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025</li>
<li>Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range</li>
<li>Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of December 31, 2024, anticipated to support operations into 2027</li>
</ul>

Y-Mabs Therapeutics Said It Is Internally Realigning Operations With The Establishment Of Two Business Units: Radiopharmaceuticals And Danyelza And Announced 2025 Priorities

GENC

Gencor Announces Receipt Of nyse Regulation Notice Regarding Late Filing Of The Annual Report On Form 10-k For The Year Ended September 30, 2024

The settlement agreement&nbsp;permits&nbsp;Sandoz&nbsp;to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances.
Similar patent litigation brought by Intra-Cellular Therapies against other parties remains pending in the U.S. District Court for the District of New Jersey.&nbsp;

Legal

ITCI

Intra-Cellular Therapies Enters Settlement Agreement With Sandoz Resolving Patent Litigation Related To CAPLYTA Patent; No Terms Disclosed

ProMIS Neurosciences Says It Initiates Phase 1B Clinical Trial (PRECISE-AD) In Alzheimer's Disease

Mizuho analyst John Baumgartner maintains Simply Good Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) with a Outperform and lowers the price target from $48 to $45.

SMPL

Mizuho Maintains Outperform on Simply Good Foods, Lowers Price Target to $45

<ul>
<li>Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO</li>
<li>Company reaffirms Fiscal 2024 financial guidance</li>
</ul>

Management

Neogenomics Announced That Chris Smith Will Retire As CEO And Board Member Effective April 1, 2025. Tony Zook, An Independent Board Member Since 2023, Will Assume The Role Of CEO At That Time

Comments

Avatar Ventures

Avatar Ventures (ATAR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga